Eli Lilly and Company’s Framework Agreement With The EU Commission For COVID-19 Treatment

Hogan Lovells advised Eli Lilly and Company on the matter.

Eli Lilly and Company was involved in a tender process and associated framework agreement with the European Commission for the procurement of a monoclonal antibody therapy for COVID-19.

The framework agreement covers the supply of up to 220,000 doses of a combination therapy of two monoclonal antibodies for the treatment of confirmed COVID-19 in patients aged 12 years and older who do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19. 

The combination therapy consisting of the two antibodies is currently under review by the European Medicines Agency (EMA). Treatment of patients will only take place after the therapy has been approved for emergency use at the national level or approved at the EU level. 

Eli Lilly Team (Legal) was led by Oliver Stahl (Senior Director Corporate Affairs), with legal support provided by Nicole Könecke (Director Legal – supply contract with BMG) and Dr. Thomas Jochheim (Senior Legal Counsel – tender and framework agreement with the EU Commission).

Hogan Lovells team for Eli Lilly included Arne Thiermann (Picture – Partner, Strategic Operations, Agreements and Regulation (SOAR) – Life Sciences, Hamburg), Ciara Kennedy-Loest (Partner, Competition, Public & EU Law, London), Fabien Roy (Partner, Medical Device and Technology, Brussels), Dr. Benjamin Göhl (Associate, Strategic Operations, Agreements and Regulation (SOAR) – Life Sciences, Munich), Katharina Kranzfelder (Senior Associate, Business Restructuring and Insolvency, Munich). 

Involved fees earner: Benjamin Göhl – Hogan Lovells; Ciara Kennedy-Loest – Hogan Lovells; Katharina Kranzfelder – Hogan Lovells; Fabien Roy – Hogan Lovells; Arne Thiermann – Hogan Lovells;

Law Firms: Hogan Lovells;

Clients: Eli Lilly and Company;

Giulia Di Palma

Author: Giulia Di Palma